Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

September 2024

Glucocorticoid sparing effect of Janus Kinase inhibitors compared to biological Disease Modifying Anti-Rheumatic Drugs in rheumatoid arthritis: A single-centre retrospective analysis

Journal Reference: Rheum. 2024 Epub ahead of print doi: 10.1093/rheumatology/keae455.

Adami G,

Bixio R,

Gatti D,

Adami et al. conducted a retrospective analysis to evaluate the GC sparing effects of JAKi versus bDMARDs in rheumatoid arthritis patients. They found that JAKi therapy was associated with a significant reduction in GC dose compared with bDMARDs. This suggests that JAKi could be more effective in reducing long-term GC exposure in RA patients.

Keywords:

Real-World

June 2024

A disease-associated gene desert directs macrophage inflammation through ETS2

Nature 2024 doi: 10.1038/s41586-024-07501-1 Epub ahead of print

Haag LM,

Papa I,

Zhang Q,

Zhang T,

Wood CS,

New FN,

Hall A,

Jiang L,

Saruhan-Direskeneli G,

Green M,

Nye E,

Stankey, et al. used functional genomics to show that the ETS2 gene is a central regulator of human inflammatory macrophages. They also found that ETS2 was disrupted by JAK inhibitors and MEK inhibitors, with multiple MEK inhibitors being shown to downregulate ETS2-target genes.

Keywords:

JAK,
MOA

February 2024

Effectiveness and Safety of Filgotinib in Rheumatoid Arthritis: A Real-life Multicentre Experience

Clin Exp Rheumatol 2024 doi 10.55563/clinexprheumatol/k78ug3 Epub ahead of print

Rizzo C,

Bursi R,

Foti R,

This real-world observational study by La Barbera, et al. confirms that filgotinib is efficacious and safe for use in the management of RA. The authors also report that improvements in clinical and laboratory features were greater in bDMARD-naïve patients with RA.